The ARID1B Phenotype: What We Have Learned so Far

被引:82
|
作者
Santen, Gijs W. E. [1 ]
Clayton-Smith, Jill [1 ]
机构
[1] Leiden Univ, Med Ctr, NL-2300 RC Leiden, Netherlands
关键词
Coffin-Siris syndrome; ARID1B; review; CHROMATIN-REMODELING COMPLEX; COFFIN-SIRIS SYNDROME; SWI/SNF COMPLEX; MUTATIONS; DELETION; CANCER; HAPLOINSUFFICIENCY; AGENESIS; PATIENT; REGION;
D O I
10.1002/ajmg.c.31414
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Evidence is now accumulating from a number of sequencing studies that ARID1B not only appears to be one of the most frequently mutated intellectual disability (ID) genes, but that the range of phenotypes caused by ARID1B mutations seems to be extremely wide. Thus, it is one of the most interesting ID genes identified so far in the exome sequencing era. In this article, we review the literature surrounding ARID1B and attempt to delineate the ARID1B phenotype. The vast majority of published ARID1B patients have been ascertained through studies of Coffin-Siris syndrome (CSS), which leads to bias when documenting the frequencies of phenotypic features. Additional observations of those individuals ascertained through exome sequencing studies helps in delineation of the broader clinical phenotype. We are currently establishing an ARID1B consortium, aimed at collecting ARID1B patients identified through genome-wide sequencing strategies. We hope that this endeavor will eventually lead to a more comprehensive view of the ARID1B phenotype. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:276 / 289
页数:14
相关论文
共 50 条
  • [1] Interstitial 6q25 Microdeletion Syndrome: ARID1B Is the Key Gene
    Ronzoni, Luisa
    Tagliaferri, Francesco
    Tucci, Arianna
    Baccarin, Marco
    Esposito, Susanna
    Milani, Donatella
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2016, 170 (05) : 1257 - 1261
  • [2] Dent disease in Poland: what we have learned so far?
    Zaniew, Marcin
    Mizerska-Wasiak, Malgorzata
    Zaluska-Lesniewska, Iga
    Adamczyk, Piotr
    Kilis-Pstrusinska, Katarzyna
    Halinski, Adam
    Zawadzki, Jan
    Lipska-Zietkiewicz, Beata S.
    Pawlaczyk, Krzysztof
    Sikora, Przemyslaw
    Ludwig, Michael
    Szczepanska, Maria
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (11) : 2005 - 2017
  • [3] Intraocular lens opacification: What have we learned so far
    Srinivasan, Sathish
    JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2018, 44 (11) : 1301 - 1302
  • [4] Editorial: Cancer Nanotheranostics: What Have We Learned So Far?
    Conde, Joao
    Tian, Furong
    de la Fuente, Jesus M.
    Baptista, Pedro V.
    Baptista, PedroV.
    FRONTIERS IN CHEMISTRY, 2016, 3
  • [5] Extracranial rhabdoid tumours: what we have learned so far and future directions
    Brennan, Bernadette
    Stiller, Charles
    Bourdeaut, Franck
    LANCET ONCOLOGY, 2013, 14 (08) : E329 - E336
  • [6] MRD Tailored Therapy in AML: What We Have Learned So Far
    Ngai, Lok Lam
    Kelder, Angele
    Janssen, Jeroen J. W. M.
    Ossenkoppele, Gert J.
    Cloos, Jacqueline
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [7] Exosomes in Inflammatory Bowel Disease: What Have We Learned So Far?
    Wang, Haichao
    Ye, Chen
    Wu, Yaling
    Yang, Pengyu
    Chen, Chunqiu
    Liu, Zhanju
    Wang, Xiaolei
    CURRENT DRUG TARGETS, 2020, 21 (14) : 1448 - 1455
  • [8] Hirschsprung Disease as a Yet Undescribed Phenotype in a Patient with ARID1B Mutation
    Takenouchi, Toshiki
    Yoshihashi, Hiroshi
    Sakaguchi, Yuri
    Uehara, Tomoko
    Honda, Masataka
    Takahashi, Takao
    Kosaki, Kenjiro
    Miyama, Sahoko
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2016, 170 (12) : 3249 - 3252
  • [9] NEO adjuvant chemotherapy in breast cancer: What have we learned so far
    Raut, Nirmal, V
    Chordiya, Nilesh
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2010, 31 (01) : 8 - 17
  • [10] Fluorescent Nanoparticle Interactions with Biological Systems: What Have We Learned so Far?
    Shang, Li
    Nienhaus, Gerd Ulrich
    COLLOIDAL NANOPARTICLES FOR BIOMEDICAL APPLICATIONS X, 2015, 9338